Search

Your search keyword '"Magnusson, Bo"' showing total 186 results

Search Constraints

Start Over You searched for: Author "Magnusson, Bo" Remove constraint Author: "Magnusson, Bo"
186 results on '"Magnusson, Bo"'

Search Results

1. Damage to residual stand caused by mechanized selection harvest in uneven-aged Picea abies dominated stands

3. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

4. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

5. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

6. Consensus-based recommendations for the management of juvenile dermatomyositis

7. Using Acceptance and Commitment Therapy in the Rehabilitation of an Adolescent Female with Chronic Pain: A Case Example

8. Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study

9. Subcutaneous nodules as a clinical biomarker of Farber disease

10. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

14. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

15. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy

16. Farber disease (acid ceramidase deficiency) natural history study: Prospective and retrospective clinical data

17. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial

18. Acid ceramidase deficiencypresenting as Farber disease: prospective and retrospective clinical data from an ongoing natural history study

20. The European network for care of children with paediatric rheumatic diseases : Care across borders

21. The European network for care of children with paediatric rheumatic diseases: Care across borders

22. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

23. Farber disease (acid ceramidase deficiency): Data from an ongoing natural history study

24. The European network for care of children with paediatric rheumatic diseases: care across borders

26. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: Combined data of more than 15,000 patients from Pharmachild and national registries

27. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis : An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

28. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis:challenges and opportunities

29. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis : challenges and opportunities

30. Consensus-based recommendations for the management of juvenile dermatomyositis

31. Consensus-based recommendations for the management of juvenile dermatomyositis

32. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative

33. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities

34. Consensus-based recommendations for the management of juvenile dermatomyositis

35. Farber disease acid ceramidase deficiency is more common than previously thought and slowly progressive disease may only be diagnosed in adulthood

36. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities

37. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis

38. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy

39. European network for care of children with paediatric rheumatic diseases: care across borders.

40. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

41. Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE)- Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis

42. Consensus-based recommendations for the management of juvenile dermatomyositis

44. Farber disease is characterized by typical features but a broad phenotypic spectrum: Selected information from a cohort of 37 patients

45. Perceived Oral Health and Care of Children with Juvenile Idiopathic Arthritis : A Qualitative Study

47. Unraveling the logics of landscape

49. SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis

50. Arbete i utomhustruckar på sågverk - en utvärdering av kamera- och monitorstöd

Catalog

Books, media, physical & digital resources